{"abstract":"The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Molecular Targeting Technologies, Inc. (MTTI); a Delaware corporation, with its principle place of business in West Chester, Pennsylvania, to practice the inventions embodied in the issued patents and patent applications listed in the Supplementary Information section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2022/10/17/2022-22476.html","cfr_references":[],"citation":"87 FR 62866","comment_url":null,"comments_close_on":"2022-11-01","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development November 1, 2022 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2022-22476","effective_on":null,"end_page":62867,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2022/10/17/2022-22476.xml","html_url":"https://www.federalregister.gov/documents/2022/10/17/2022-22476/prospective-grant-of-exclusive-patent-license-radiotherapeutics-for-nasopharyngeal-cancer","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2022-22476?publication_date=2022-10-17","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2022-10-17/2022-22476/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":156,"last_updated":"2026-11-22 14:15:04 -0500"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-10-17/pdf/2022-22476.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-22476.pdf?1665751526","publication_date":"2022-10-17","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2022/10/17/2022-22476.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T02:20:02Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":62866,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Radiotherapeutics for Nasopharyngeal Cancer","toc_doc":"Radiotherapeutics for Nasopharyngeal Cancer","toc_subject":"Licenses; Exemptions, Applications, Amendments etc.:\n","topics":[],"type":"Notice","volume":87}